Metocurine

DB01336

small molecule approved

Deskripsi

Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine. A2393

Struktur Molekul 2D

Berat 652.8189
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1214 Data
Buprenorphine Metocurine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Metocurine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Metocurine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Metocurine.
Hydrocodone Metocurine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Metocurine.
Magnesium sulfate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Metocurine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Metocurine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Metocurine.
Mirtazapine Metocurine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Metocurine.
Orphenadrine Metocurine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Metocurine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Metocurine.
Pramipexole Metocurine may increase the sedative activities of Pramipexole.
Ropinirole Metocurine may increase the sedative activities of Ropinirole.
Rotigotine Metocurine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Metocurine.
Sodium oxybate Metocurine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Metocurine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Metocurine.
Thalidomide Metocurine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Metocurine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Capreomycin The therapeutic efficacy of Metocurine can be increased when used in combination with Capreomycin.
Cyclosporine The therapeutic efficacy of Metocurine can be increased when used in combination with Cyclosporine.
Doxycycline The therapeutic efficacy of Metocurine can be increased when used in combination with Doxycycline.
Lymecycline The therapeutic efficacy of Metocurine can be increased when used in combination with Lymecycline.
Framycetin The therapeutic efficacy of Metocurine can be increased when used in combination with Framycetin.
Clomocycline The therapeutic efficacy of Metocurine can be increased when used in combination with Clomocycline.
Quinine The therapeutic efficacy of Metocurine can be increased when used in combination with Quinine.
Vancomycin The therapeutic efficacy of Metocurine can be increased when used in combination with Vancomycin.
Tigecycline The therapeutic efficacy of Metocurine can be increased when used in combination with Tigecycline.
Oxytetracycline The therapeutic efficacy of Metocurine can be increased when used in combination with Oxytetracycline.
Chloroquine The therapeutic efficacy of Metocurine can be increased when used in combination with Chloroquine.
Demeclocycline The therapeutic efficacy of Metocurine can be increased when used in combination with Demeclocycline.
Mecamylamine The therapeutic efficacy of Metocurine can be increased when used in combination with Mecamylamine.
Tobramycin The therapeutic efficacy of Metocurine can be increased when used in combination with Tobramycin.
Tetracycline The therapeutic efficacy of Metocurine can be increased when used in combination with Tetracycline.
Gentamicin The therapeutic efficacy of Metocurine can be increased when used in combination with Gentamicin.
Etacrynic acid The therapeutic efficacy of Metocurine can be increased when used in combination with Etacrynic acid.
Quinidine The therapeutic efficacy of Metocurine can be increased when used in combination with Quinidine.
Metacycline The therapeutic efficacy of Metocurine can be increased when used in combination with Metacycline.
Netilmicin The therapeutic efficacy of Metocurine can be increased when used in combination with Netilmicin.
Neomycin The therapeutic efficacy of Metocurine can be increased when used in combination with Neomycin.
Streptomycin The therapeutic efficacy of Metocurine can be increased when used in combination with Streptomycin.
Colistimethate The therapeutic efficacy of Metocurine can be increased when used in combination with Colistimethate.
Kanamycin The therapeutic efficacy of Metocurine can be increased when used in combination with Kanamycin.
Rolitetracycline The therapeutic efficacy of Metocurine can be increased when used in combination with Rolitetracycline.
Magnesium oxide The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium oxide.
Magnesium cation The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium cation.
Paromomycin The therapeutic efficacy of Metocurine can be increased when used in combination with Paromomycin.
Lincomycin The therapeutic efficacy of Metocurine can be increased when used in combination with Lincomycin.
Ribostamycin The therapeutic efficacy of Metocurine can be increased when used in combination with Ribostamycin.
Geneticin The therapeutic efficacy of Metocurine can be increased when used in combination with Geneticin.
Apramycin The therapeutic efficacy of Metocurine can be increased when used in combination with Apramycin.
Gentamicin C1a The therapeutic efficacy of Metocurine can be increased when used in combination with Gentamicin C1a.
Neamine The therapeutic efficacy of Metocurine can be increased when used in combination with Neamine.
Arbekacin The therapeutic efficacy of Metocurine can be increased when used in combination with Arbekacin.
Viomycin The therapeutic efficacy of Metocurine can be increased when used in combination with Viomycin.
Puromycin The therapeutic efficacy of Metocurine can be increased when used in combination with Puromycin.
Magnesium hydroxide The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium hydroxide.
Magnesium trisilicate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium trisilicate.
Magnesium chloride The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium chloride.
Magnesium acetate tetrahydrate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium acetate tetrahydrate.
Magnesium carbonate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium carbonate.
Magnesium citrate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium citrate.
Magnesium glycinate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium glycinate.
Magnesium Aluminum Silicate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium Aluminum Silicate.
Dihydrostreptomycin The therapeutic efficacy of Metocurine can be increased when used in combination with Dihydrostreptomycin.
Hygromycin B The therapeutic efficacy of Metocurine can be increased when used in combination with Hygromycin B.
Sisomicin The therapeutic efficacy of Metocurine can be increased when used in combination with Sisomicin.
Plazomicin The therapeutic efficacy of Metocurine can be increased when used in combination with Plazomicin.
Magnesium silicate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium silicate.
Penimepicycline The therapeutic efficacy of Metocurine can be increased when used in combination with Penimepicycline.
Magnesium aspartate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium aspartate.
Isepamicin The therapeutic efficacy of Metocurine can be increased when used in combination with Isepamicin.
Magnesium gluconate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium gluconate.
Magnesium orotate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium orotate.
Magnesium phosphate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium phosphate.
Magnesium acetate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium acetate.
Procainamide The therapeutic efficacy of Metocurine can be increased when used in combination with Procainamide.
Dantrolene The therapeutic efficacy of Metocurine can be increased when used in combination with Dantrolene.
Piperacillin The therapeutic efficacy of Metocurine can be increased when used in combination with Piperacillin.
Magnesium stearate The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium stearate.
Colistin The therapeutic efficacy of Metocurine can be increased when used in combination with Colistin.
Aclidinium The risk or severity of adverse effects can be increased when Metocurine is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Metocurine.
Mirabegron The risk or severity of urinary retention can be increased when Metocurine is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Metocurine is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Metocurine.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Metocurine.
Tiotropium The risk or severity of adverse effects can be increased when Metocurine is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Metocurine is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Metocurine is combined with Umeclidinium.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Metocurine.
Glycopyrronium The risk or severity of adverse effects can be increased when Metocurine is combined with Glycopyrronium.
Spironolactone Spironolactone may increase the neuromuscular blocking activities of Metocurine.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Metocurine is combined with Botulinum toxin type A.
Glucagon Metocurine may increase the gastrointestinal motility reducing activities of Glucagon.

Target Protein

Neuronal acetylcholine receptor subunit alpha-2 CHRNA2
Muscarinic acetylcholine receptor M2 CHRM2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 9915319
    Spacek A, Neiger FX, Krenn CG, Hoerauf K, Kress HG: Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. Anesthesiology. 1999 Jan;90(1):109-12.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul